RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
← catalyst calendarNCT04514653 · readout ≤ 12 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With REGENXBIO Inc..
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
146actual
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-08-25 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2020-08-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
- Biological: Ranibizumab
- Genetic: ABBV-RGX-314 Dose 1 — also filed as Combination Product
- Genetic: ABBV-RGX-314 Dose 2 — also filed as Combination Product
- Genetic: ABBV-RGX-314 Dose 3 — also filed as Combination Product
- Drug: Local Steroid
- Drug: Topical Steroid
- Genetic: ABBV-RGX-314 Dose 4 — also filed as Combination Product
Primary outcome
what the primary-completion date above is the date OFMean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) score
measured 40 weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed